HBM Holdings (HKG:2142) repurchased HK$10 million worth of shares on Feb. 7, the most for biotech firms on the Hong Kong Stock Exchange, according to a Monday filing with the bourse.
The buyback is a part of a HK$40 million buyback plan to enhance shareholder value.
CEO and chairman of the board Jingsong Wang increased his stake in the company and did not rule out further stake increase.
With cash reserves of HK$1.43 billion, the company is strengthening its business by partnering with companies like Windward Bio and Kodiak Sciences. These collaborations aim to advance research and develop innovative treatments in key areas such as immunology and ophthalmology.
The company's shares were up by 15% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.